MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

European regulators say Alzheimer’s therapy Leqembi should be rejected

LONDON — European regulators on Friday said that an Alzheimer’s therapy from Eisai and Biogen should be rejected, again diverging from their U.S. counterparts on

July 26, 2024

Promising new approach to combat HIV

Researchers at Université de Montréal’s affiliated hospital research center, the CRCHUM, say the discovery could help lessen and even eliminate viral loads in people undergoing

September 11, 2024

Daniel Carcillo Gives Insight Into The Mind Of An Athlete

For World Mental Health Day, we had a special edition of The Dales Report Psychedelic Exclusive. Daniel Carcillo, the Chief Operating Officer of Healing CREI

October 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.